Caroline Seymour

In non–small cell lung cancer, EGFR mutations, MET exon 14 skipping mutations, and HER2 mutations are common mutation for which directed therapies are available.

The combination of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is moving into the frontline setting for patients with diffuse large B-cell lymphoma.

A more severe symptom burden was seen in patients with isolated thrombocytopenia vs those with isolated anemia, according to findings from the phase 3 PERSIST-1 and PAC203 trials in myelofibrosis.

Adding magrolimab to azacytidine and venetoclax led to a rate of high responses in high-risk de novo and secondary acute myeloid leukemia.

Among premenopausal patients, the addition of everolimus to endocrine therapy improved iDFS and OS, which is hypothesis generating, said Mariana Chavez-MacGregor, MD.

Post hoc CheckMate 214 results show that nivolumab plus ipilimumab extend progression and overall survival in patient with advanced sarcomatoid renal cell carcinoma who have not be previously treated.

Patients with more than 2 tertiary lymphoid structures, high Ki-67, and PD-1 positivity had high response rates to nivolumab plus ipilimumab.

The rate of 2-year overall survival was nearly doubled with atezolizumab vs vinorelbine or gemcitabine in advanced platinum-ineligible non–small cell lung cancer.

Patients with locally advanced head and neck squamous cell carcinoma did not show statistically significant improvement in event-free survival with pembrolizumab plus chemoradiation vs chemoradiation alone.

Data from the Defi trial shows that nirogacestat had a significant reduction in the risk of disease progression for patients with progressive desmoid tumors.

The combination of talquetamab and daratumumab has the potential to demonstrate synergistic clinical activity, and preclinical studies have shown that the addition of daratumumab enhanced talquetamabmediated lysis of multiple myeloma cells.

Amivantamab in combination with lazertinib and chemotherapy combination demonstrated encouraging responses in EGFR-mutant non–small cell lung cancer.

Sotorasib and RMC-4630 elicited promising preliminary activity in pretreated and KRAS G12C inhibitor–naïve patients with non–small cell lung cancer.

Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.

At the 2022 ASCO Annual Meeting findings from the phase, 3 DETERMINATION trial showed off the survival benefit when adding autologous stem cell transplant and lenalidomide maintenance after RVd treatment for patients with newly diagnosed multiple myeloma.

Encouraging efficacy signals in heavily pretreated patients with advanced solid tumor has been demonstrated in AURELIO-03 trial, and will be further evaluated in AURELIO-304.

Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

In the prospective, double-blind, phase 2 randomized controlled trial, in which investigators evaluated the efficacy and safety of topical ruxolitinib, a novel gene signature was identified.

Mixed results were reported from the phase 2 ARIES clinical trial at the 2022 ASCO GU meeting.

Phase 3 MAGNITUDE study results show positive efficacy for niraparib plus abiraterone in HRR gene-altered metastatic castration resistant prostate cancer.

In an interview with Lt Col Yovanni Casablanca, MD, discussed the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

An overall survival improvement for the combination of durvalumab and tremelimumab has been reported by the HIMALAYA clinical trial lead investigator.

Although cytokine release syndrome can occur in patients treated with APVO436, the event can be managed with steroids without adversely affecting treatment.

With an increase in genomic testing for colorectal cancer, new targeted treatments have also been developed to treat patients with specific disease characteristics.

Polatuzumab vedotin-piiq added to the R-CHOP regimen elicited a high progession-free survival rate in patients with newly-diagnosed diffuse large B-cell lymphoma.

Findings from the phase 3 ASCEMBL trial showed a consistent improvement in major molecular response rate and depth of response without any new or worsening adverse effects when treating with asciminib versus bosutinib in patients with chronic-phase chronic myeloid leukemia.

In an analysis of the phase 3 GLOW study, data showed promise for the use of ibrutinib/venetoclax in the frontline setting.

A pooled analysis of results from the randomized phase 2 SAFIR02_BREAST and SAFIR-PI3K trials show promise for the use of multigene sequencing to select targeted therapy for metastatic breast cancer.

Most patients with advanced HCC have resistance to PD-1 monotherapy. In other cancers, response to PD-1 inhibitors has been associated with an inflamed microenvironment with effector T cells and active IFN-α signaling.

In patients with HER2-positive, metastatic colorectal cancer, fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels.